Malignant Exocrine Pancreas Neoplasm — Trials

Malignant Exocrine Pancreas Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 360
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +39.4%
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 51–100 of 166 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05985655	Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE)	recruiting	Phase 1 / Phase 2	230	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY	3	Aug 13, 2026	clinicaltrials
NCT06399757	A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	100	Apollo Therapeutics LtdINDUSTRY	1